Muhammad Waqas1,2, Rimal H Dossani1,2, Modhi Alkhaldi3, Jocelyn Neveu4, Justin M Cappuzzo1,2, Jaims Lim1,2, Asham Khan1,2, Victoria Lazarov4, Andre Monteiro1,2, Jason M Davies1,2,5,6,7, Adnan H Siddiqui1,2,6,7,8, Elad I Levy1,2,6,7,8. 1. Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. 2. Department of Neurosurgery, Gates Vascular Institute at Kaleida Health, Buffalo, NY, USA. 3. Depratment of Neurology, Abdulrhman Bin Faisal University, Imam, Saudi Arabia. 4. Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. 5. Department of Bioinformatics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA. 6. Canon Stroke and Vascular Research Center, University at Buffalo, Buffalo, NY, USA. 7. Jacobs Institute, Buffalo, NY, USA. 8. Department of Radiology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA.
Abstract
INTRODUCTION: The Flow Redirection Endoluminal Device (FRED; MicroVention) is a dual-layered flow diverter used for the treatment of intracranial aneurysms. The objective of this systematic review was to compile device-related safety and effectiveness data. METHODS: The literature from January 1, 2013 to April 30, 2021 was searched for studies describing use of the FRED for intracranial aneurysm treatment irrespective of aneurysm location and morphology. The review included anterior and posterior circulation ruptured and unruptured saccular, fusiform or dissection, and blister aneurysms. MeSH terms related to "flow re-direction endoluminal device" and "FRED for aneurysms" were used. Data related to indication, complications, and rates of aneurysm occlusion were retrieved and analyzed. RESULTS: Twenty-two studies with 1729 intracranial aneurysms were included in this review. Overall reported morbidity was 3.9% (range 0-20%). Overall procedure-related mortality was 1.4% (range 0-6%). Complication rates fell into 5 categories: technical (3.6%), ischemic (3.8%), thrombotic or stenotic (6%), hemorrhagic (1.5%), and non-neurological (0.8%). The aneurysm occlusion rate between 0 and 3 months (reported in 11 studies) was 47.8%. The occlusion rate between 4 and 6 months (reported in 14 studies) was 73.8%. Occlusion rates continued to increase to 75.1% at 7-12 months (reported in 10 studies) and 86.6% for follow-up beyond 1 year (reported in 10 studies). CONCLUSION: This review indicated that the FRED is a safe and effective for the treatment of intracranial aneurysms. Future studies should directly compare the FRED with other flow diverters for a better understanding of comparative safety and effectiveness among the different devices.
INTRODUCTION: The Flow Redirection Endoluminal Device (FRED; MicroVention) is a dual-layered flow diverter used for the treatment of intracranial aneurysms. The objective of this systematic review was to compile device-related safety and effectiveness data. METHODS: The literature from January 1, 2013 to April 30, 2021 was searched for studies describing use of the FRED for intracranial aneurysm treatment irrespective of aneurysm location and morphology. The review included anterior and posterior circulation ruptured and unruptured saccular, fusiform or dissection, and blister aneurysms. MeSH terms related to "flow re-direction endoluminal device" and "FRED for aneurysms" were used. Data related to indication, complications, and rates of aneurysm occlusion were retrieved and analyzed. RESULTS: Twenty-two studies with 1729 intracranial aneurysms were included in this review. Overall reported morbidity was 3.9% (range 0-20%). Overall procedure-related mortality was 1.4% (range 0-6%). Complication rates fell into 5 categories: technical (3.6%), ischemic (3.8%), thrombotic or stenotic (6%), hemorrhagic (1.5%), and non-neurological (0.8%). The aneurysm occlusion rate between 0 and 3 months (reported in 11 studies) was 47.8%. The occlusion rate between 4 and 6 months (reported in 14 studies) was 73.8%. Occlusion rates continued to increase to 75.1% at 7-12 months (reported in 10 studies) and 86.6% for follow-up beyond 1 year (reported in 10 studies). CONCLUSION: This review indicated that the FRED is a safe and effective for the treatment of intracranial aneurysms. Future studies should directly compare the FRED with other flow diverters for a better understanding of comparative safety and effectiveness among the different devices.
Authors: H Luecking; T Engelhorn; S Lang; P Goelitz; S Kloska; K Roessler; A Doerfler Journal: AJNR Am J Neuroradiol Date: 2017-01-19 Impact factor: 3.825
Authors: Hannes Luecking; Arnd Doerfler; Philipp Goelitz; Philip Hoelter; Tobias Engelhorn; Stefan Lang Journal: Interv Neuroradiol Date: 2019-10-09 Impact factor: 1.610
Authors: C J Griessenauer; M A Möhlenbruch; P Hendrix; C Ulfert; C Islak; M Sonnberger; T Engelhorn; E Müller-Thies-Broussalis; T Finkenzeller; M Holtmannspötter; J-H Buhk; W Reith; A Simgen; H Janssen; N Kocer; M Killer-Oberpfalzer Journal: AJNR Am J Neuroradiol Date: 2020-02-27 Impact factor: 3.825
Authors: Leopoldo Guimaraens; Elio Vivas; Jesus Saldaña; Juan Carlos Llibre; Alberto Gil; Ernest Balaguer; Ana Rodríguez-Campello; Elisa Cuadrado-Godia; Angel Ois Journal: J Neurointerv Surg Date: 2019-10-25 Impact factor: 5.836